Perceive Biotherapeutics is a biotechnology company pioneering novel technologies and therapeutics in ophthalmology.
Perceive Biotherapeutics has raised $78.0M in total funding. The most recent round was Series B. The last funding was announced in January 2023.
Perceive Biotherapeutics's investors include Catalio Capital Management, Deerfield, Johnson & Johnson Innovation, Braidwell, Retinal Degeneration Fund.
Perceive Biotherapeutics is headquartered in South San Francisco, United States.
Perceive Biotherapeutics is a biotechnology company pioneering novel technologies and therapeutics in ophthalmology.
Perceive Biotherapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Perceive Biotherapeutics — Funding & Investors." VCBacked, January 5, 2023, https://www.vcbacked.co/company/perceive-biotherapeutics. Accessed August 15, 2026.
VCBacked. (2023). Perceive Biotherapeutics — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/perceive-biotherapeutics
{{cite web |title=Perceive Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/perceive-biotherapeutics |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated